CClinicalTrials.gg
Sign In
Status unknownNCT03734874Updated Nov 8, 2018

The Effects of Hesperidin on Metabolic Syndrome

An interventional study of hesperidin and control in Metabolic Syndrome, sponsored by National Nutrition and Food Technology Institute. Status unknown at 1 site in Iran, Islamic Republic of. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2018-11-08.

Sponsored by National Nutrition and Food Technology Institute · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Nov 2018), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Jun 2018, registered Oct 2018).
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

To study the effects of Hesperidin supplement in patients with metabolic syndrome, 50 patients will be randomly allocated to control group or 2 capsules Hesperidin for 12 weeks; both groups will be advised to adherence the investigators' diet and exercise program too. At the first and the end of the intervention, metabolic factors will be assessed and compared between groups.

02

Conditions studied

  • Metabolic Syndrome
03

In context

Metabolic Syndrome

1,964 studies on the registry are indexed under Metabolic Syndrome; 330 are open to participants now.

This study's planned enrollment of 50 is below the median of 60 across 1,460 interventional studies indexed under Metabolic Syndrome.

Browse Metabolic Syndrome studies →

Lead sponsor

National Nutrition and Food Technology Institute is the lead sponsor of 62 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age of 18 to 70 years
  • having 3 of 5 of high blood sugar, hypertension, high TG, high waist circumference, low HDL

Exclusion criteria

Exclusion Criteria:

  • pregnancy or lactation
  • A history of Cardiovascular disease, Pulmonary disease, Renal disease \& Celiac disease; Cirrhosis
  • Following program to lose weight in recent 3 mo
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Active comparator
    hesperidin

    Dietary Supplement: hesperidin

  • Placebo comparator
    control

    Other: control

Interventions

  • Dietary supplementhesperidin

    500 mg hesperidin as two capsuls

  • Othercontrol

    no supplementation

06

What researchers measure

Primary outcomes

  1. Metabolic syndrome: Number of participants with treated metabolic syndrome

    number of participants with treated metabolic syndrome

    Time frame: 12 weeks

07

Study locations

1 of 1 sites recruiting
  • National Nutrition and Food Technology Research Institute
    Tehran, Iran, Islamic Republic of
    • azita hekmatdoost, MD,PhD · Contact
    Recruiting
08

References and documents

Publications

  • Yari Z, Movahedian M, Imani H, Alavian SM, Hedayati M, Hekmatdoost A. The effect of hesperidin supplementation on metabolic profiles in patients with metabolic syndrome: a randomized, double-blind, placebo-controlled clinical trial. Eur J Nutr. 2020 Sep;59(6):2569-2577. doi: 10.1007/s00394-019-02105-2. Epub 2019 Dec 16. PubMed 31844967 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 8, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03734874
Lead sponsor
National Nutrition and Food Technology Institute
Responsible party
Dr Azita Hekmatdoost (Principal Investigator, National Nutrition and Food Technology Institute) — Principal investigator
First posted
Nov 8, 2018
Start date
Jun 1, 2018
Primary completion
Nov 1, 2018 (estimated)
Completion
Dec 1, 2018 (estimated)
Last update
Nov 8, 2018

Study contacts

azita Hekmatdoost, MD.PhD
Contact
a_hekmat2000@yahoo.com
+98-21-22077424

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Metabolic Syndrome→

Other studies from this sponsor

National Nutrition and Food Technology Institute

Start the discussion